Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
These 2 Numbers Should Scare Every Biogen Shareholder
07:15am, Sunday, 16'th Jul 2023
Biogen's latest drug launch could make it a lot of money through 2028. If it does, it'll reverse a long-running trend of weak growth.
Why Isn't Biogen Stock Soaring After This Major FDA Approval?
08:15am, Thursday, 13'th Jul 2023
The FDA gave full approval for Alzheimer's drug Leqembi in July. Despite the positive news, Biogen's stock didn't take off.
Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug
12:30pm, Monday, 10'th Jul 2023
Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.
Biogen shares ‘an under-owned turnaround story,' Jefferies analysts say
08:58am, Monday, 10'th Jul 2023
Shares of Biogen Inc. BIIB, -3.48%, which last week received a milestone U.S. Food and Drug Administration approval for Alzheimer's treatment Leqembi, “remain an under-owned turnaround story,” and
FDA Approves New Alzheimer's Drug But Creators Biogen And Eisai Stock Slides
08:00am, Monday, 10'th Jul 2023
Eisai saw its stock fall 4.67% on the news and Biogen was down 2.07%.
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
07:11am, Monday, 10'th Jul 2023
Stocks often react differently from the way you think they might. That happened on July 7 as shares of Biogen Inc. NASDAQ: BIIB swooned 2.88% in heavy trading volume following news of full regulatory
Biogen And Alzheimer's Disease: Too Early To Celebrate
11:52pm, Sunday, 09'th Jul 2023
The FDA has granted full approval to Biogen and Eisai's anti-amyloid antibody drug Leqembi, but there is skepticism about its efficacy and safety. The approval led to a drop in Biogen's stock, in part
Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?
06:00am, Sunday, 09'th Jul 2023
The FDA just approved Biogen's new Alzheimer's treatment Leqembi. This could become the company's next billion-dollar product -- and kickstart growth.
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
07:00am, Saturday, 08'th Jul 2023
Patients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.
Dow Jones Today: Index Falls After Soft Jobs Report
05:00pm, Friday, 07'th Jul 2023
Job creation came in lower than expected, and investors are still worried about higher interest rates, sending the Dow lower by about 190 points.
Three-Stock Lunch: Meta, Biogen and Levi Strauss
03:33pm, Friday, 07'th Jul 2023
Gina Sanchez, chief market strategist at Lido Advisors, joins ‘Power Lunch' to discuss her thoughts on three stocks: Meta, Biogen and Levi Strauss.
FDA approves Biogen's Leqembi: the Alzheimer's drug will ‘surprise to the upside'
02:32pm, Friday, 07'th Jul 2023
Biogen Inc (NASDAQ: BIIB) is trading down this morning even though the Food and Drug Administration awarded full approval to its Alzheimer's drug – Leqembi.
Sales of Alzheimer's drug Leqembi may be slow initially but could pick up in 2024
01:59pm, Friday, 07'th Jul 2023
Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term.
Biogen's Alzheimer's Drug Rollout Could Be Slow
01:17pm, Friday, 07'th Jul 2023
Biogen has said it doesn't expect to clear a profit on Alzheimer's treatment Leqembi, which was approved by the FDA Thursday, until late 2024.
Markets Mixed Midday as Job Growth Slows
12:25pm, Friday, 07'th Jul 2023
U.S. equities were mixed at midday on Friday, July 7, 2023 after the government's June jobs report showed job creation slowed.
